Unknown

Dataset Information

0

A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine.


ABSTRACT: The clinical use of endogenous neuropeptides has historically been limited due to pharmacokinetic issues, including plasma stability and blood-brain barrier permeability. In this study, we show that the rapidly metabolized Leu-enkephalin (LENK) neuropeptide may become pharmacologically efficient owing to a simple conjugation with the lipid squalene (SQ). The corresponding LENK-SQ bioconjugates were synthesized using different chemical linkers in order to modulate the LENK release after their formulation into nanoparticles. This new SQ-based nanoformulation prevented rapid plasma degradation of LENK and conferred on the released neuropeptide a notable antihyperalgesic effect that lasted longer than after treatment with morphine in a rat model of inflammation (Hargreaves test). The biodistribution study as well as the use of brain-permeant and -impermeant opioid receptor antagonists indicated that LENK-SQ NPs act through peripherally located opioid receptors. This study represents a novel nanomedicine approach, allowing the specific delivery of LENK neuropeptide into inflamed tissues for pain control.

SUBMITTER: Feng J 

PROVIDER: S-EPMC6374102 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7546706 | biostudies-literature
| S-EPMC6993230 | biostudies-literature
| S-EPMC8704573 | biostudies-literature
| S-EPMC5045404 | biostudies-literature
| S-EPMC11293877 | biostudies-literature
| S-EPMC7487096 | biostudies-literature
| S-EPMC7914648 | biostudies-literature
| S-EPMC2677986 | biostudies-literature
| S-EPMC2803117 | biostudies-other
| S-EPMC4690805 | biostudies-literature